Epigral Ltd (IN:EPIGRAL)
:EPIGRAL
Want to see IN:EPIGRAL full AI Analyst Report?
EPIGRAL Stock Chart & Stats
₹1244.30
-₹4.30(-0.24%)
At close: 4:00 PM EST
₹1244.30
-₹4.30(-0.24%)
Day’s Range― - ―
52-Week Range₹806.20 - ₹2,114.30
Previous CloseN/A
Volume42.70K
Average Volume (3M)1.86K
Market Cap
₹45.89B
Enterprise Value₹55.75B
Total Cash (Recent Filing)₹485.70M
Total Debt (Recent Filing)₹5.37B
Price to Earnings (P/E)14.5
Beta1.49
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)93.51
Shares Outstanding43,141,340
10 Day Avg. Volume1,295
30 Day Avg. Volume1,859
Financial Highlights & Ratios
PEG Ratio-1.15
Price to Book (P/B)1.57
Price to Sales (P/S)1.38
P/FCF Ratio-535.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)93.8
Revenue Forecast (FY)₹33.92B
Bulls Say, Bears Say
Bulls Say
Strengthened Balance SheetLeverage has declined to roughly 0.26x equity and equity has grown, improving financial flexibility. Lower debt reduces interest burden and bankruptcy risk, enabling the firm to fund capex, weather downturns, or pursue M&A without immediate refinancing pressure.
Durable MarginsHealthy operating and net margins indicate structural price-setting ability or cost discipline relative to peers. Sustained margins provide a cushion against cyclical revenue swings and support mid-term profitability and return on invested capital.
Positive Operating Cash FlowCore operations generate positive cash flow, showing the business can fund working capital and service obligations from operating activity. This operational cash generation supports stability and provides time to address free cash flow issues without immediate external financing.
Bears Say
Negative Free Cash FlowFree cash flow deterioration signals that reported profits are not translating into distributable cash. Negative FCF constrains the company’s ability to invest, pay sustainable dividends, or reduce debt, and may force asset sales or external financing if persistent.
Margin CompressionMaterial margin compression and weaker earnings power suggest rising input costs, pricing pressure, or reduced operational leverage. Persisting compression erodes returns, limits reinvestment capacity, and makes performance more sensitive to demand volatility.
Weak/volatile Revenue GrowthVery weak or volatile revenue growth undermines scalability and forecasting reliability. Inconsistent top-line trends make margin recovery harder, amplify cash conversion swings, and raise execution risk for strategic initiatives over the medium term.
Epigral Ltd News
EPIGRAL FAQ
What was Epigral Ltd’s price range in the past 12 months?
Epigral Ltd lowest stock price was ₹806.20 and its highest was ₹2114.30 in the past 12 months.
What is Epigral Ltd’s market cap?
Epigral Ltd’s market cap is ₹45.89B.
When is Epigral Ltd’s upcoming earnings report date?
Epigral Ltd’s upcoming earnings report date is Aug 03, 2026 which is in 50 days.
How were Epigral Ltd’s earnings last quarter?
Epigral Ltd released its earnings results on May 02, 2026. The company reported ₹19 earnings per share for the quarter, beating the consensus estimate of ₹14.3 by ₹4.7.
Is Epigral Ltd overvalued?
According to Wall Street analysts Epigral Ltd’s price is currently Overvalued.
Does Epigral Ltd pay dividends?
Epigral Ltd pays a Semiannually dividend of ₹5 which represents an annual dividend yield of 0.46%. See more information on Epigral Ltd dividends here
What is Epigral Ltd’s EPS estimate?
Epigral Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Epigral Ltd have?
Epigral Ltd has 43,141,340 shares outstanding.
What happened to Epigral Ltd’s price movement after its last earnings report?
Epigral Ltd reported an EPS of ₹19 in its last earnings report, beating expectations of ₹14.3. Following the earnings report the stock price went up 0.894%.
Which hedge fund is a major shareholder of Epigral Ltd?
Currently, no hedge funds are holding shares in IN:EPIGRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Epigral Ltd
Epigral Limited operates in the chemical sector, focusing on the production and global distribution of chlor-alkali products and their associated derivatives. Its diverse product range encompasses chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash. Additionally, the company is involved in the trading of agrochemical products. Epigral caters to an extensive list of industries, including CPVC pipes and fittings, wind energy, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soaps and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. Incorporated in 2007 and based in Ahmedabad, India, the company was formerly known as Meghmani Finechem Limited until it adopted the name Epigral Limited in August 2023.
Technical Analysis
Gufic Biosciences Limited
―
Marksans Pharma Limited
―
Shilpa Medicare Limited
―
Strides Pharma Science Ltd
―
Supriya Lifescience Limited
―